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ABSTRACT 
 
Several cell types contribute to atherosclerotic calcification. Myeloid calcifying cells (MCCs) 
are monocytes expressing osteocalcin (OC) and bone alkaline phosphatase (BAP). Herein, 
we tested whether MCCs promote atherosclerotic calcification in vivo. We show that the 
murine spleen contains OC+BAP+ cells with a phenotype similar to human MCCs, a high 
expression of adhesion molecules and CD11b, and capacity to calcify in vitro and in vivo. 
Injection of GFP+ OC+BAP+ cells into 8- or 40-week ApoE-/- mice led to more extensive 
calcifications in atherosclerotic areas after 24 or 4 weeks, respectively, compared to control 
OC-BAP- cells. Despite OC+BAP+ cells had a selective transendothelial migration capacity, 
tracking of the GFP signal revealed that presence of injected cells within atherosclerotic 
areas was an extremely rare event and GFP mRNA was undetectable by qPCR of lesion 
extracts. By converse, injected OC+BAP+ cells persisted in the bloodstream and bone 
marrow up to 24 weeks, suggesting a paracrine effect. Indeed, OC+BAP+ cell conditioned 
medium (CM) promoted calcification by cultured vascular smooth muscle cells (VSMC) more 
than CM from OC-BAP- cells. A genomic and proteomic investigation of MCCs identified 
allograft inflammatory factor (AIF)-1 as a potential candidate of this paracrine activity. AIF-1 
stimulated VSMC calcification in vitro and monocyte-specific (CD11b-driven) AIF-1 
overexpression in ApoE-/- mice increased calcium content in atherosclerotic areas. In 
conclusion, we show that murine OC+BAP+ cells correspond to human MCCs and promote 
atherosclerotic calcification in ApoE-/- mice, through paracrine activity and modulation of 
resident cells by AIF-1 overexpression. 
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INTRODUCTION 
 
Atherosclerosis is a complex inflammatory disease of the artery wall [10]. Ectopic 
calcification is a common feature of advanced atherosclerotic plaques and it affects vascular 
function [2]. While extensively calcified lesions may be more stable than lipid-rich lesions, 
spotty neointimal calcifications are believed to increase lesion vulnerability and probability of 
rupture [23, 26]. The mechanisms that drive vascular calcification are manifold and there are 
several cell types potentially involved. Medial calcification appears to arise mainly from 
osteogenic transdifferentiation of resident smooth muscle cells [23, 26] or mesenchymal 
cells, such as adventitial cells and pericytes [12, 20]. On the other hand, circulating calcifying 
cells may contribute to intimal calcification within atherosclerotic lesions or heart valves, by 
recruitment from the bone marrow and bloodstream [7, 9, 20]. According to recent data [12], 
a new paradigm indicates that circulating calcifying cells may have pathophysiological, 
clinical and therapeutic implications in vascular and bone disorders. We have recently 
identified a subpopulation of circulating monocyte/macrophage lineage cells which show 
calcifying ability using in vitro assays and in vivo models of ectopic calcification, such as the 
subcutaneous Matrigel plug. Such cells express osteocalcin (OC) and bone alkaline 
phosphatase (BAP), retain myeloid features and are increased in the circulation and bone 
marrow of diabetic patients [11]. These myeloid calcifying cells (MCCs) can also be obtained 
after culture of peripheral blood mononuclear cells (PBMCs) and undergo calcification in vitro 
and when implanted into subcutaneous Matrigel plugs [11]. Although OC+BAP+ cells were 
more frequent in extensively calcified atherosclerotic lesions of diabetic patients compared to 
less calcified lesions of non diabetic patients, whether MCCs from the bloodstream truly 
contribute to vascular calcification was unclear. Therefore, the present study was designed to 
test the hypothesis that OC+BAP+ cells promote calcification of atherosclerotic lesions in 
mice.  
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MATERIALS AND METHODS 
 
Animals. C57Bl/6 mice constitutively expressing GFP (strain C57BL/6-Tg(CAG-
EGFP)1Osb/J from Charles River laboratories) were used as donors of bone marrow cells to 
be injected into 8- or 40-week old ApoE-/- mice (strain C57Bl/6.129P2-Apoetm1UncJ from 
Charles River laboratories). Wild type C57Bl/6 mice were from the in-house colony. Eight 
week old ApoE-/- mice were fed a standard chow diet, housed in controlled humidity and 
temperature conditions, with free access to food and water for 24 weeks after cell injection to 
allow development of atherosclerosis. Forty week old ApoE-/- mice, also fed a standard chow 
diet, had already developed advanced atherosclerosis, and were maintained for 2 weeks 
after cell injection. Generation of C57Bl/6 ApoE-/-AIF-1tg mice has been described previously 
[18, 19]. Paraffin-embedded samples from 15 week old  ApoE-/-AIF-1tg and ApoE-/-AIF-1wt 
mice on a standard chow diet were obtained and analyzed. The protocol was approved by 
the Animal Ethical Committee of the University of Padova and experiments were conducted 
according to the NIH principles of laboratory animal care (publication no. 85-23, revised 
1985). 
 
Culture of murine calcifying cells. Murine calcifying cells were isolated from the mouse 
spleen as a large source of mononuclear cells, using a protocol similar to that optimized to 
yield human MCCs [11]. The spleen was surgically removed from wild type C57Bl/6 mice 
before killing, minced and filtrated to obtain a single cell suspension. Red blood cells were 
lysed and mononuclear cells separated using Histopaque 1077 (Sigma-Aldrich). Cells 
(3x106/cm2) were plated in 24-well plates coated with Matrigel (Becton Dickinson) for 3 
weeks in complete osteogenic medium (MesenCultTM medium + osteogenic stimuli, Stem 
Cells Technologies Inc.). The medium was changed first after 1 week and then every 3 days. 
Two weeks after plating, beta-glycerophosphate (final concentration 3.5 mM) was added to 
the culture for 1 week to stimulate calcium deposition. At the end of the 3-week culture 
protocol, wells were stained with Von Kossa and Alizarin red.  
 
Flow cytometry and cell sorting. Spleen-derived mononuclear cells from GFP+ animals 
were stained with PE-conjugated anti-OC (R&D System) and APC-conjugated anti-BAP 
(R&D Systems, clone B4-78) monoclonal antibodies for cell sorting (BD FACSAria). GFP+ 
sorted cells were injected into ApoE-/- mice via the tail vein (5x105/animal). 
For further characterization of spleen-derived OC+BAP+ cells, in separate experiments, cells 
were co-stained with FITC-conjugated anti-mouse CD45, CD11b, CD3, CD90, CD29, CD44 
monoclonal antibodies (all from BD). The percentage of these leukocyte and mesenchymal 
markers on OC+BAP+ cells was quantified and compared to expression in OC-BAP- cells on a 
FACSCanto instrument (BD). AIF-1 detection by FACS was performed on gated human 
OC+BAP+ and OC-BAP- cells using a FITC-conjugated clone Iba1 mAb (Abcam cat# 
AB15691). Flow cytometry was also used to track and characterize GFP+ cells retrieved from 
peripheral blood, bone marrow and spleen of injected mice, at time of killing. After gating the 
GFP+ signal, cells were analyzed for the percentage expression of OC and BAP. 
 
In vivo calcification assay. To test the ability of sorted cells to calcify, we performed an in 
vivo assay by implanting freshly sorted murine OC-BAP- and OC+BAP+ cells embedded into 
500 µL of Matrigel (BD) into the flanks of C57Bl/6 recipient mice. Ten days later, before 
killing, mice were subjected to a micro computed tomography scan on a microCT eXplore 
Locus system (GE Healthcare). 
 
Transendothelial migration. To test the ability of OC+BAP+ cells to undergo 
transendothelial migration, we used a modified transwell migration assay, as previously 
described [16]. Briefly, freshly isolated, unlabelled PBMC from healthy young blood donors 
were left to adhere to or transmigrate through a monolayer of green fluorescence-labelled 
(PKH67, Sigma Aldrich) human aortic endothelial cells (HAECs, Lonza) grown to confluence 
on the filter membrane of sterile 3 micron-pore, 12-well format transwell migration inserts (BD 
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Falcon). After 6 hours, transmigrating PBMC were harvested from the lower compartment, 
while non-adherent (floating) and adherent cells were harvested from the upper compartment 
by sequential washing/detachment. The 3 cell fractions (floating, adherent and migrated) 
were individually stained with OC and BAP as described above, to look for enrichment of 
OC+BAP+ cells. Endothelial cells were separated from PBMC during the analysis by a 
multiparametric gating strategy. Experiments were performed with 3 different PBMC donors 
each time in duplicate. Higher percentages of OC+BAP+ cells in the adhered and migration 
fraction were considered indicative of selective transendothelial migratory capacity compared 
with OC or BAP-negative cells. 
 
Culture of VSCM with conditioned media. To test the capacity of circulating calcifying cells 
to modulate SMC calcification via paracrine signals, bovine aortic smooth muscle cells 
(BSMCs) were coltured with conditioned media from human OC+BAP+ or OC-BAP- cells. 
Explant-derived primary BSMCs were used between passage 4 and 6 and cultured in plastic 
dishes as previously described [22]. At confluence in 24-well plates, cells were treated with 
400 µL of cell culture media (DMEM containing 5% FBS, 100 U/mL penicillin, 100 µg/mL 
streptomycin) supplemented with 100 µL of 24h-conditioned media from freshly sorted 
OC+BAP+ or OC-BAP- cells. To promote calcium deposition, Pi was added to the culture (final 
concentration 2.0 mmol/L) and the media was changed every third day. After 6 days calcium 
deposition was quantified by using the O-cresolphtalein complexone method (Chema 
Diagnostica, Italy). To test the pro-calcific effect of AIF-1, SMC were incubated with 0-1-5 nM 
recombinant human AIF-1. Experiments were performed in triplicate. 
 
Gene expression analysis. Cells used for these analysis were derived by FACS sorting of 
OC-BAP- and OC+BAP+ cells from PBMC obtained by healthy young blood donors. 
Microarray. Total RNA was isolated using TRIzol (Invitrogen) followed by cleanup with the 
RNeasy Mini Kit (Qiagen). RNA integrity was evaluated with the Agilent 2100 Bioanalyzer 
(Agilent Technologies, Palo Alto, CA) and quantified with a NanoVue spectrophotometer (GE 
Healthcare Life Sciences, Baie d'Urfe, QC). For gene expression profiling, 250ng of RNA 
was hybridized to Human Genome U133 Plus 2.0 Arrays (Affymetrix). Expression values 
were generated from fluorescence signals using the robust multi-array average procedure. 
Specifically, intensity levels have been background adjusted, normalized using quantile 
normalization, and log2 expression values calculated using median polish summarization 
and Entrez custom chip definition files for human arrays (version 15.1.0). The gene 
expression data are published online at GEO series GSE47060.  
Real time quantitative PCR. Total RNA was extracted using RNeasy kit (Qiagen), then 
reverse transcribed to generate cDNA using the First-Strand cDNA Synthesis Kit from 
Invitrogen. Gene-specific primer pairs were  designed using Primer-BLAST (NCBI) and were 
validated prior to use by gradient PCR and gel analysis to test for optimal annealing 
temperature, reaction efficiency and specificity. Real time PCR with Fast SYBR Green 
detection was performed using an 7900HT Fast Real-Time qPCR System (Applied 
Biosystems) and the following primers: mouse Ubiquitin C (reference gene) FW    
5’GCCCAGTGTTACCACCAAGA 3'  RV 5’CCCATCACACCCAAGAACA 3'; mouse AIF-1 FW 
5’ GTTTGGACGGCAGATCCTCA 3’  RV 5’ CAGGGATTTGCAGGGAGGAA 3’ ; Human 
Actin beta (reference gene) FW5’  GGATGCCACAGGACTCCA 3';  RV5’  
AGAGCTACGAGCTGCCTGAC 3'; human AIF-1 FW5’ ACCAGGGATTTACAGGGAGG 3’ 
RV5’ GTTTGGAGGGCAGATCCTCA 3’. GFP-FW 5’CTTCTTCAAGTCCGCCATGC 3'  REV 
5’GTGTCGCCCTCGAACTTCAC 3'. Expression data were normalized to the  mean of 
housekeeping gene ubiquitin C to control the variability in expression levels and were 
analyzed using the 2(-∆∆CT ) method.  
 
Proteomic analysis. Circulating cells were lysed by sonication on ice in a hypotonic buffer 
(50 mM HEPES pH 7.5, 1% Triton, protease inhibitor cocktail). Proteins (120 µg) from each 
sample were precipitated overnight at -20 °C with cold acetone. Protein pellets were 
dissolved in 120 µl of TEAB 0.5 M, reduced, alkylated and trypsin digested according to the 
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iTRAQ manufacturer’s instructions. Samples were split in two aliquots of 60 µg to perform 
two technical replicates with tag swapping. Following iTRAQ labelling, samples were pooled 
and vacuum concentrated. The dried iTRAQ labeled sample was dissolved in 400 µl of 
equilibration buffer (5 mM KH2PO4, 25% acetonitrile, pH 2.9), and fractionated with a strong 
cation exchange cartridge (AB Sciex, Canada) in a step-wise mode, using the following 
concentrations of KCl: 50, 100, 150, 200, 350 mM. Each SCX fraction was then dried under 
vacuum, resuspended in 500 µl of 0.1% formic acid, desalted using C18 cartridges (Sep-
Pack, C18, Waters). Samples from each SCX fraction were dried under vacuum and then 
dissolved in 50 µl of 0.1% formic acid, obtaining a final concentration of 1 µg/µl. The MS 
analyses were performed on a LTQ-Orbitrap XL mass spectrometer (Thermo Fisher 
Scientific) coupled with a nano-HPLC Ultimate 3000 (Dionex - Thermo Fisher Scientific). The 
same samples fractionated with a Tempo™ LC MALDI Spotting System (AB Sciex) were 
also analyzed with a MALDI-TOF/TOF 4800 mass spectrometer (AB Sciex). Collected data 
were analyzed using Proteome Discoverer 1.2 (Thermo Fisher Scientific) connected to a 
Mascot Search Engine (version 2.2.4, Matrix Science, UK). MS/MS data obtained from from 
each SCX fraction and with the different instrumental platforms were treated as technical 
replicate for quantification purposes. Data were filtered considering as positive hits the 
proteins identified with at least two unique peptides with medium confidence (FDR 5%) and 
quantified with at least 2 independent peptides. OC+BAP+ over OC-BAP- cell ratio ≥1.6 was 
set as threshold for protein over-expression. 
 
Histology and confocal microscopy. ApoE-/- mice injected with GFP+OC+BAP+ or GFP+OC-
BAP- cells (n=5/group for both long-term and short-term experiments) were killed and 
dissected under a surgical microscope to collect the aortic sinus, aortic arch, and innominate 
arteries. Seven-micrometer thick transversal cryosections at each atherosclerotic site were 
stained with Von Kossa and Alizarin red for analysis of atherosclerotic calcification. The 
pentachromic staining was used to characterize atherosclerotic lesion components, 
according to the manufacturer’s instructions (American MasterTech). Custom ImageJ plug-
ins were used for quantification of calcium deposits. 
For extraction and quantification of calcium from paraffin-embedded tissue samples of 15 
week old AIF-1Tg ApoE-/- and control mice, paraffin was removed by melting blocks at 60°C. 
Tissues samples were put in xylene 100% for 10 minutes at room temperature and then 
Hydrated through a descending alcohol series to water. Samples were put in 100 ul HCl 0.6 
N, heated at 99° for 5 minutes and lysed through 2 cycles of freezing and thawing by snap 
freezing in liquid nitrogen and thawing on ice. Samples were left overnight in HCl 0.6 N 
before mechanical disruption with TissueLyser (Qiagen). HCl was neutralised with 100 ul of 
0.1 N NaOH, 0.1% SDS. Samples were centrifuged at room temperature at 13000xG. 
Surnatant were assed for calcium concentration by using O-cresolphtalerin complexome 
method (Chema Diagnostica, Italy). Protein concentration was assessed by using NanoVue 
Plus (Ge Life Sciences). 
To track the fate of injected GFP+ cells, we tried different strategies of confocal microscopy 
(Leica TCS SP5). The endogenous GFP signal was weak and barely above background 
green signal, determined by necrotic debris, oxidized lipids and calcium deposits within 
atherosclerotic lesions. When stained with an anti-GFP antibody (Rabbit Anti-GFP, Life 
Technologies, UK) and green secondary antibody (Donkey Anti-Rabbit DyLight 488, Jackson 
ImmunoResearch, UK), signal amplification was insufficient to discriminate positive areas 
from the background. We therefore used a blue-labelled secondary antibody (Donkey Anti-
Rabbit AMCA, Jackson) to amplify the GFP signal and nuclei were counterstained in red with 
propidium iodine (PI). With this combination, only cells with simultaneous blue and green 
cytoplasm and a defined red nuclear shadow were considered as homed GFP+ cells. 
 
Statistical analysis. Data are expressed as mean ± standard error. Comparison between 2 
or more groups were performed using ANOVA and Student’s t test, respectively. Bonferroni 
correction was applied to account for multiple testing and statistical significance was 
accepted at p<0.05. 
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RESULTS 
 
Isolation of murine calcifying cells. We have previously shown that culture of human 
PBMC in osteogenic conditions yields a population of OC- and BAP- expressing cells that 
calcify in vitro and in vivo. Herein, we have used a similar protocol to isolate murine calcifying 
cells in vitro: spleen-derived mononuclear cells were able to mineralize 3 weeks after plating, 
as shown by Von Kossa and Alizarin red staining (Figure 1). These data suggest that the 
spleen harbours a subset of calcifying cells, that can be used for in vivo experiments. 
 
Murine OC+BAP+ cells promote ectopic calcification in vivo. Using FACS, we isolated 
OC+BAP+ and OC-BAP- cells from the spleen of C57Bl/6 mice to obtain a pure population of 
calcifying cells and the respective control cells. By surface immunophenotyping, we found 
that OC+BAP+ cells expressed leukocyte (CD45) and myeloid (CD11b, CD29, CD44) markers 
with no expression of the mesenchymal stem cell marker CD90 (Thy-1). Importantly, 
compared to OC-BAP- cells, OC+BAP+ cells expressed higher levels of the adhesion 
molecules CD11b and CD29, which are important for homing to the vascular wall. Freshly 
sorted murine OC+BAP+ and OC-BAP- cells were embedded into Matrigel plugs and 
implanted subcutaneously into the flanks of syngeneic C57Bl/6 mice. After 2 weeks, mice 
were subjected to a MicroCT scan, that revealed the presence of grossly calcified nodules at 
the sites of OC+BAP+ cell implantation, while no calcification was seen by contralateral OC-
BAP- cells (Figure 1). 
 
OC+BAP+ cells undergo transendothelial migration in vitro. We reasoned that the 
capacity of circulating calcifying cells to promote atherosclerotic calcification might be  linked 
to their transendothelial migration activity. We tested the ability of human OC+BAP+ cells to 
adhere and transmigrate across an endothelial layer using a modified transwell assay with 
human aortic endothelial cells (HAEC). We found that the percentage of OC+BAP+ cells in 
the adherent and migrated fraction was significantly enriched than in the floating 
compartment, indicating the selective adherence and transendothelial migration of OC+BAP+ 
cells compared to OC- or BAP-negative cells (Figure 2). 
 
Murine OC+BAP+ cells promote calcification of early and advanced atherosclerosis. To 
test the hypothesis that OC+BAP+ cells promote atherosclerotic calcification, we injected 
these cells into ApoE-/- mice using either a long term experiment in young mice (EXP-1) or a 
short-term experiment in aged mice (EXP-2). Figure 3A shows the experimental design. 
Freshly isolated OC+BAP+ or OC-BAP- cells (5 x 105 / mouse) from the spleen of mice 
constitutively expressing GFP were injected into 8-wks old ApoE-/- mice, fed a standard chow 
diet for 24 weeks. Before euthanasia, blood, spleen and bone marrow cells were collected for 
FACS analysis. After 24 weeks, GFP+ cells were still present in the bloodstream and 
accounted for about 0.01% of circulating leukocytes. OC+BAP+ cells were preferentially found 
in peripheral blood, while OC-BAP- cells were preferentially located in the bone marrow. For 
both OC+BAP+ and OC-BAP- cells, about 60% of injected GFP+ cells that were still present in 
the circulation retained their original phenotype, while the remaining 40% had lost or 
acquired OC and/or BAP (Figure 3). 
Atherosclerotic lesions in young ApoE-/- mice fed a standard chow diet for 24 weeks were 
mainly located in the aortic sinus. Von Kossa and Alizarin red staining showed a 2.3-fold 
higher degree of calcification (% calcified area) in mice injected with OC+BAP+ compared to 
mice injected with control OC-BAP- cells (Figure 4A). Freshly isolated OC+BAP+ or OC-BAP- 
GFP+ cells were also injected into 40-wks old ApoE-/- mice, fed a standard chow diet for 2 
weeks. Two weeks after injection, GFP+ cells were present in the bloodstream and 
accounted for about 0.01% of circulating leukocytes. These mice had developed extensive 
atherosclerotic lesions. Mice injected with OC+BAP+ cells showed increased calcified areas in 
the innominate artery, aortic arch and aortic sinus compared to mice injected with OC-BAP- 
cells and to non-injected coeval ApoE-/- mice, used as controls (Figure 4B). 
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Characterization of lesion components was performed with pentachrome (Movat’s) staining, 
in which black colouring is for nuclei and elastic fibres, yellow for collagen fibres, blue for 
mucin and bright red for fibrin and red for muscle. Lesions derived from old ApoE-/- mice 
(EXP-2) injected with OC+BAP+ cells showed significant changes in such components. 
Compared to injection of OC-BAP- cells, injection of OC+BAP+ cells increased collagen 
accumulation in the innominate artery and aortic arch and increased mucin content in the 
aortic arch and sinus, while other components showed no changes (Figure 5). 
 
Presence of injected cells at sites of vascular disease. In order to track the fate of 
injected cells, we used different strategies to detect the GFP signal. Several apparently 
spontaneously green fluorescent cells (nuclei surrounded by green fluorescence, Figure 6A) 
were detectable in sections of atherosclerotic lesions, but non-specific signal was also 
abundant and the hypothetical GFP signal was barely above the background, especially near 
areas of oxidized lipid accumulation and calcification. Amplification of the GFP signal with an 
indirect green fluorescent immunodetection slightly improved resolution, but did not allow a 
clear discrimination from background, especially in advanced and complex lesions. 
Therefore, we used a blue-conjugated indirect anti-GFP staining and counterstained nuclei in 
red because autofluorescence of atherosclerotic lesions was lower in the blue than in the 
green channel. This allowed us to better identify injected cells as a red nucleus surrounded 
by a blue cytoplasm (anti-GFP) co-localized with endogenous green fluorescence (Figure 
6B-D). With this specific method, we detected a very small number of injected cells within 
atherosclerotic lesions (on average less than 1 cell per section), with no difference in 
atherosclerotic areas of mice injected with OC+BAP+ compared to mice injected with OC-
BAP- cells. As this highly specific method may lead to an underestimation of the amount of 
GFP+ cells in the lesions, we performed a qPCR analysis of the GFP mRNA in vascular 
specimen extracts obtained from OC+BAP+ and OC-BAP- cell-injected mice of both EXP-1 
and EXP-2. We found that the GFP transcript was undetectable (or below detection limit) at 
both timepoints, as it was undistinguishable from the negative control represented by a non-
GFP tissue (Figure 6E). Sequencing of the late amplification products revealed only no GFP 
signal (not shown). These data indicate that the local contribution of injected MCCs to 
atherosclerotic calcification is very small or negligible and we hypothesize that they may 
affect calcification of resident cells by paracrine signals. 
 
Allograft inflammatory factor-1 contributes to the paracrine pro-calcific activity of 
MCCs. To dissect the molecular mechanisms driving the pro-calcific potential of MCCs, we 
performed an extensive genomic and proteomic investigation of human OC+BAP+ cells 
(MCCs) relative to control OC-BAP- cells. We aligned gene and protein IDs to identify those 
that were significantly upregulated in MCCs and found 57 genes/proteins (Online Resource 
1, Figure 7A). A pathway analysis run on the DAVID platform [15] identified calcium handling 
as the second most enriched functional annotation cluster. Among calcium-binding proteins, 
allograft inflammatory factor-1 (AIF-1) was strongly upregulated as gene (4.6-fold) and 
protein (3.1-fold). We validated AIF-1 mRNA upregulation in freshly sorted human and 
mouse OC+BAP+ versus OC-BAP- cells, as well as AIF-1 protein expression by flow 
cytometry on human cells (Figure 7B). Based on the paracrine hypothesis, VSMC were 
challenged with conditioned media from freshly isolated human OC+BAP+ cells or control OC-
BAP- cells. We found that VSMC exposed to OC+BAP+ cell conditioned medium showed a 
2.5-fold higher calcification compared to the control medium and a significant 40% increased 
calcification compared to VSMC exposed to OC-BAP- cell conditioned medium. In addition, 
VSMC incubated with 5 nM AIF-1 showed increased calcification compared with the control 
condition (Figure 7C).  
To confirm that excess AIF-1 expression drives vascular calcification by MCCs in vivo, we 
analyzed samples from ApoE-/-AIF-1tg mice, in which overexpression of AIF-1 is driven by the 
CD11b promoter and is thus specific for the monocyte-macrophage lineage, to which MCCs 
belong. It has been shown previously that these mice have accelerated atherosclerosis [18]. 
After calcium extraction from tissue samples including the aortic sinus, aortic valve and aortic 
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arch, we found that, compared to control ApoE-/- mice, ApoE-/-AIF-1tg mice have a marked 
increase in calcium content (Figure 7D).  
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DISCUSSION 
 
We show that injection of OC+BAP+ cells into young and old ApoE-/- mice strongly increased 
calcification of early and advanced atherosclerotic lesions. We have recently demonstrated 
that human OC+BAP+ cells derive from the myeloid lineage, form mineralized nodules in vitro 
and calcify when implanted subcutaneously into nude mice. These myeloid calcifying cells 
(MCCs) were detected by immunohistochemistry in atherosclerotic lesions and their 
circulating levels were increased in patients with diabetes and/or cardiovascular disease, but 
it was unclear whether circulating OC+BAP+ cells homed to the diseased vessel wall or they 
contributed to calcification through other mechanisms. Herein, we first show that OC+BAP+ 
cells have a selective capacity to adhere and migrate across the endothelium, lending 
support to their involvement in vascular disease. Second, we found that the murine spleen 
contains a subpopulation of mononuclear cells that calcify in vitro. Spleen-derived OC+BAP+ 
cells calcified in vivo and displayed an antigenic profile similar to that of human MCCs. 
OC+BAP+ cells had a higher expression of integrin adhesion molecules CD11b and CD29 
than control OC-BAP- cells, again supporting their vasculotrophic activity. Therefore, we 
devised a cell transfer protocol to study the ability of labelled OC+BAP+ MCCs and control 
OC-BAP- cells to modulate calcification in the atherosclerosis-prone ApoE-/- mice, as a proof-
of-concept of the MCC activity in vivo. We studied both early and advanced lesions 24 and 2 
weeks after cell injection, respectively. Remarkably, 60% of injected GFP+ cells maintained 
their original phenotype (OC+BAP+ or OC-BAP-) and represented 0.01% of circulating 
leukocytes at 24 weeks after injection. This indicates that injected cells steadily circulated in 
the recipient mice. While injected OC+BAP+ cells were present mainly in the bloodstream and 
not in the bone marrow, OC-BAP- cells repopulated the bone marrow to a small extent. These 
findings are in line with the previous observations that human OC+BAP+ cells, unlike OC-
BAP- cells, are long lived and not necessarily residing in the bone marrow [11]. We used the 
spleen as a source of cells to be injected into ApoE-/- mice because it has been recently 
shown that the spleen functions as a buffer of monocytic cells that accelerate atherosclerosis 
[8], and is a candidate reservoir of MCCs. In addition, OC+BAP+ cells from the bone marrow 
would be contaminated by mesenchymal stem cells expressing OC and BAP [21], which are 
rarer in the spleen.  
The most striking result of the present study is that injection of OC+BAP+ cells into ApoE-/- 
mice strongly increased atherosclerotic calcification of early lesions over 24 weeks and of 
advanced lesions over 2 weeks. This is the sought proof-of-concept demonstration that 
MCCs are involved in atherosclerotic calcification in vivo and supports the role of circulating 
cells in this phenomenon [12]. To  track the fate of injected cells, we used a genetic approach 
in which cells are spontaneously fluorescent owing to genomic expression of GFP. Detection 
of GFP signal in atherosclerotic areas is complicated by the extensive autofluorescence of 
necrotic debris, oxidized lipids and calcium deposits. It has been demonstrated that a 
multiparametric and stringent confocal microscopy analysis is needed to reliably detect the 
presence of injected in cardiovascular tissues [4, 5]. Thus, the simple enumeration of green 
fluorescent cells in the sections of complex tissues likely leads to an overestimation of the 
homing phenomenon. To overcome this bias, we used specific and stringent criteria to detect 
injected cells and found that, despite the strong effect on calcification, the number of injected 
cells present in the lesions at time of sacrifice was very low. Consistently, qPCR performed 
on RNA isolated from atherosclerotic lesions of mice injected with GFP+ OC+BAP+ and OC-
BAP- cells was unable to detect the GFP transcript. The most reasonable explanation are 
that either OC+BAP+ die in the process of calcification or that calcification results from a 
paracrine activity. As it would be surprising that extensive neointimal calcifications were 
entirely attributable to circulating cells, we hypothesized that OC+BAP+ cells might indirectly 
promote calcification of smooth muscle cells, the most abundant source of calcifying cells in 
the vessel wall [27]. Indeed, conditioned medium obtained from OC+BAP+ cells induced 
calcification of VSMC more than conditioned medium from OC-BAP- cells. To dissect the 
molecular machinery driving the pro-calcific potential of MCCs, we performed an in-depth 
and unprecedented genomic and proteomic investigation. We detected a series of 57 genes 
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and their products that were upregulated in OC+BAP+ cells compared to OC-BAP- controls. 
Much interestingly, the calcium handling functional annotation pathway, which is involved in 
calcification, was enriched in this cluster of genes/proteins. Indeed, 12/57 genes/proteins 
(21%) have calcium-binding activity and AIF-1 was among the most upregulated ones. AIF-1 
has been previously shown to induce atherosclerosis, restenosis and vascular inflammation 
by stimulation of VSMC and monocyte-macrophage activity [3, 18, 24, 29]. SM-restricted 
AIF-1 overexpressing mice on a high fat diet develop accelerated atherosclerosis [24]. By 
converse, in vivo AIF-1 silencing decreased neointimal hyperplasia in wire-injured rat carotid 
arteries [25]. AIF-1 is induced by interferon-γ, which affects the VSMC phenotype [6]. 
Therefore, we focused on AIF-1 as a candidate mediator of the pro-calcific potential of 
MCCs. AIF-1 was able to induce calcification of cultured VSMC, supporting the paracrine 
hypothesis. Furthermore, transgenic ApoE-/- mice with CD11b-driven AIF-1 overexpression 
showed exacerbated aortic calcification, strongly indicating that AIF-1 activity in monocyte-
macrophages stimulates vascular calcification and further supporting the role of AIF-1 in 
MCCs. Despite atherosclerosis in these 15-weeks old AIF-1tg mice fed a chow diet was 
mainly located at the aortic sinus, detailed information about the exact site of excess 
calcification (plaques, valves, whole aorta, media or adventitia) is presently missing and is a 
matter of future research. AIF-1 is an actin-binding protein that is also secreted in the 
extracellular fluids and its serum concentrations are correlated with cardiovascular risk 
factors [14]. This notion supports the potential role of AIF-1 as a MCC-derived systemic 
paracrine factor. 
In addition to AIF-1, several other calcium-binding proteins were found to be upregulated in 
MCCs, including S100-A8/9 that have been previously implicated in atherosclerosis [1]. 
Therefore, mechanisms other than AIF-1 likely contribute to the pro-calcific effect of MCCs, 
explaining why AIF-1 supplementation induced a smaller increase in VSMC calcification 
compared to MCC conditioned medium. 
The paracrine hypothesis reconciles the low number of GFP+ cells in the lesions with the 
extensive calcifications and also provides an explanation for the inconsistent literature about 
the role of circulating cells in vascular calcification [12]. Using genetic lineage tracking 
models, Naik et al. recently reported that most (80-98%) calcifying cells in atherosclerotic 
lesions of ApoE-/- and LDLr-/- mice are derived form local smooth muscle cells and that 
circulating cells provide a much smaller contribution [20]. Herein, we suggest that the 
paracrine activity of circulating myeloid cells is critical for stimulation of calcification by 
resident cells. This scenario is not surprising, as myeloid cells play major roles in the 
development and progression of atherosclerosis, mainly by secretory activity and release of 
cellular components upon cell death [13, 17, 28, 30]. In addition, this figure is similar to that 
shown for BM-derived smooth muscle cells, which are rarely found in atherosclerotic 
plaques, but significantly promote development of the lesion [31]. In this framework, our data 
indicate that OC+BAP+ cells are the pro-calcific subpopulation of monocytes, and suggest 
these MCCs and AIF-1 represent therapeutic targets to counter vascular calcification.  
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FIGURE LEGENDS 
 
Figure 1. Isolation and characterization of murine MCCs. C57Bl/6 mice were used as 
donors and cells were isolated from the spleen. Total spleen mononuclear cells were plated 
in osteogenic medium and showed the presence of calcifying cells. Murine OC+BAP+ and 
OC-BAP- cells were isolated by FACS from the spleen mononuclear cell population, 
embedded in Matrigel plugs and implanted subcutaneously in syngeneic recipient mice. Ten 
days later, a microCT scan revealed calcifications at sites of OC+BAP+ cell implantation. 
Cells isolated from the murine spleen were also characterized by flow cytometry to determine 
surface markers expressed by OC+BAP+ and OC-BAP- cells (*p<0.05 versus OC-BAP- cells). 
 
Figure 2. Transendothelial migration. A) A modified transwell assay was used to study 
migration of human mononuclear cells across an endothelial monolayer. B) The floating, 
adherent and migrated fraction were collected and stained with OC and BAP to identify the 2 
cell populations of interest (OC+BAP+ and OC-BAP-). C) The percentage of OC+BAP+, 
OC+BAP-, OC-BAP+ and OC-BAP- cells in the adhered and migrated fractions are reported as 
x-fold versus the percentage in the floating fraction. Only OC+BAP+ showed significant 
enrichment in the adhered and migrated fractions, while the other population remained 
unchanged or showed depletion (*p<0.05 versus floating; #p<0.05 versus migrated). On the 
bottom right, the absolute percentages of the 4 populations of cells in the original PBMC 
fraction is reported. 
 
Figure 3. Cell injection protocols. A) Design of the cell transfer experiments. We tested 
whether injection of isolated OC+BAP+ MCCs or control OC-BAP- cells modified 
atherosclerotic calcification in recipient ApoE-/- mice. To this end, we devised a long-term (24 
weeks) study on young (8-week old) ApoE-/- mice (EXP-1) and a short-term (2 weeks) study 
on old (40-week) ApoE-/- mice (EXP-2). These complementary experiments provided 
information on the role of MCCs on calcification of early and advanced atherosclerotic 
lesions. B-E) Tracking of GFP+ cells 24 weeks after injection. In EXP-1, 24 weeks after 
injection, GFP+ cells accounted for about 0.01% of circulating leukocytes. GFP+OC+BAP+ 
cells (representative plot in B) were about 70% more frequent than GFP+OC-BAP- cells 
(representative plot in C). GFP+OC-BAP- cells were preferentially located in the bone marrow 
(D). Interestingly, about 60% of injected GFP+OC+BAP+ cells and GFP+OC-BAP- cells 
maintained their OC and BAP expression profiles 24 weeks after injection (E). 
 
Figure 4. Atherosclerotic calcification. A) In young ApoE-/- mice of EXP-1, atherosclerosis 
was almost exclusively detected in the aortic sinus. At this site, mice injected with OC+BAP+ 
cells showed more than doubled calcifications compared to mice injected with OC-BAP- cells, 
as assessed by Von Kossa staining (*p<0.05; n=5/group). B) In old ApoE-/- mice, 
atherosclerosis developed extensively in the aortic sinus, innominate artery and aortic arch. 
At each of these sites, mice injected with OC+BAP+ cells showed larger calcified areas 
compared to mice injected with OC-BAP- cells and to non-injected coeval ApoE-/- mice, as 
assessed by Von Kossa and Alizarin red stainings (*p<0.05 versus both OC-BAP- and non 
injected) n=5/group). 
 
Figure 5. Characterization of atherosclerotic lesions. Sections from atherosclerotic 
lesions of OC+BAP+ and OC-BAP- cell injected mice were stained using the pentachrome 
protocol in which the black colouring is for nuclei and elastic fibres, yellow for collagen fibres, 
blue for mucin and bright red for fibrin and red for muscle. Representative sections are 
shown. Quantification was performed for collagen and mucin content and for other 
components (elastic fibers, muscle and fibrin) altogether (*p<0.05 for OC+BAP+ versus OC-
BAP-). 
 
Figure 6. Tracking of injected cells in atherosclerotic lesions. For tracking injected GFP+ 
cells in atherosclerotic areas, we used different strategies (see text). Representative confocal 
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microscopy images show nuclei in red, anti-GFP immunostaining in blue, and spontaneous 
GFP signal in green. A) Several putative GFP+ injected cells in a section of atherosclerotic 
plaque from mice injected with OC+BAP+ cells in EXP-2 (arrowheads). B) Two putative 
GFP+ cells within an innominate atherosclerotic lesion of a mice injected with OC+BAP+ cells 
in EXP-2. Inserts in the upper lane show a nucleated (red) cell with a green and blue GFP+ 
cytoplasm (arrow), interpreted as an injected cell. Within a few micrometers, an unspecific 
GFP signal in present (asterisk). Inserts in the bottom lane show a calcified area that was 
hyperfluorescent in all channels, suggesting an unspecific signal. However, the central 
nuclear shadow in the green and blue channel might indicate the presence of a calcified 
injected cell. C) A putative injected GFP+ cells close to a small calcification within an aortic 
arch atherosclerotic lesion of a mice injected with OC+BAP+ cells in EXP-2. Inserts show a 
red nucleus surrounded by blue and green GFP+ cytoplasm (arrow). In the close vicinity, an 
enlongated vertical calcification, hyperfluorescent in all channels and devoid of a nuclear 
shadow (asterisk) can be interpreted as a calcification. D) A nucleated cells with cytoplasmic 
GFP signal in the green and blue channel close to a non-GFP cell and a non-nucleated 
green and blue signal. Scale bar 50 micron. E) qPCR analysis of the GFP transcript in RNA 
samples extracted from atherosclerotic specimen of OC+BAP+ or OC-BAP- cell injected mice 
(samples of interest). The positive and controls were muscle samples from a constitutively 
expressing GFP mouse and a wild type (GFP-neg) mouse, respectively. The amplification 
plots show that there was no difference between the samples of interest and the negative 
control. Sequencing of the amplification products from the samples of interest revealed no 
GFP sequence. 
 
Figure 7. Transcriptomic/proteomic analysis of MCCs and AIF-1 validation. A) The 
discovery strategy to detect gene/proteins potentially associated with calcification. Fold-
change enrichment values in human OC+BAP+ versus OC-BAP- cells for gene and protein 
expression and reported in the scatter plot. We selected the most upregulated gene/proteins 
based on the arbitrary 1.6-fold enrichement threshold. Alignment of these 57 genes with the 
respective proteins is reported in Online Table 1. A pathway analysis run on the David 
platform identified 7 pathways with the reported enrichment score. Based on functional 
annotation of this sample of gene/proteins, we extracted calcium-binding proteins, as those 
potentially involved in ectopic calcification. Their protein and gene enrichment in OC+BAP+ 
versus OC-BAP- cells is reported. B) Overexpression of AIF-1 on OC+BAP+ versus OC-BAP- 
cells was validated by gene expression in sorted mouse and human cells, and was also 
confirmed by flow cytometry identification of the protein in human gated OC+BAP+ and OC-
BAP- cells. C) Bovine VSMC cells were cultured for 6 days in the presence of control medium 
(CTRL) or conditioned medium from human OC-BAP- and OC+BAP+ cells (left panel), or with 
increasing concentrations of AIF-1 (right panel). Each condition was supplemented with 
inorganic phosphate to obtain a final concentration of 2.0 mmol/L. Calcification was 
estimated by quantifying the calcium/protein ratio at the end of the culture period. *p<0.05 
compared to control (n=3/condition). D) The role of AIF-1 overexpression in vascular 
calcification was validated in vivo by analyzing the extent of calcium content in tissue 
samples including the aortic sinus, valves and arch of myeloid specific (CD11b-driven) 
overexpressing (TG) ApoE-/- mice and the relevant ApoE-/- controls (*p<0.05). The left panel 
shows representative histological staining of the aortic sinus showing increased 
atherosclerosis in ApoE-/- AIF-1TG mice. 
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Ca2+ BINDING PROTEINS
Uniprot ID Gene ID Description Protein enrichment Gene enrichment
P08670 7431 Vimentin OS=Homo sapiens GN=VIM PE=1 SV=4 - [VIME_HUMAN] 3.482238179 2.930761841
P06702 6280 Protein S100-A9 OS=Homo sapiens GN=S100A9 PE=1 SV=1 - [S10A9_HUMAN] 3.447432623 6.192923044
P52209 5226 6-phosphogluconate dehydrogenase, decarboxylating OS=Homo sapiens GN=PGD PE=1 SV=3 - [6PGD_HUMA 3.226353428 2.360113683
P55008 199 Allograft inflammatory factor 1 OS=Homo sapiens GN=AIF1 PE=1 SV=1 - [AIF1_HUMAN] 3.053542225 4.613849631
P05164 4353 Isoform H14 of Myeloperoxidase OS=Homo sapiens GN=MPO - [PERM_HUMAN] 2.947806291 2.055420623
Q01469 2171 Fatty acid-binding protein, epidermal OS=Homo sapiens GN=FABP5 PE=1 SV=3 - [FABP5_HUMAN] 2.855224467 1.892795612
Q9UBR2 1522 Cathepsin Z OS=Homo sapiens GN=CTSZ PE=1 SV=1 - [CATZ_HUMAN] 2.817810665 2.602898311
Q96QH2 84106 PML-RARA-regulated adapter molecule 1 OS=Homo sapiens GN=PRAM1 PE=1 SV=2 - [PRAM_HUMAN] 2.754025666 8.057007381
P05109 6279 Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1 - [S10A8_HUMAN] 2.65451622 3.299429455
Q10588 683 ADP-ribosyl cyclase 2 OS=Homo sapiens GN=BST1 PE=1 SV=2 - [BST1_HUMAN] 2.62924268 9.567197008
P23141 1066 Liver carboxylesterase 1 OS=Homo sapiens GN=CES1 PE=1 SV=2 - [EST1_HUMAN] 2.566576887 5.883519836
P60903 6281 Protein S100-A10 OS=Homo sapiens GN=S100A10 PE=1 SV=2 - [S10AA_HUMAN] 2.56093783 3.057574286
Q96CX2 115207 BTB/POZ domain-containing protein KCTD12 OS=Homo sapiens GN=KCTD12 PE=1 SV=1 - [KCD12_HUMAN] 2.521254741 5.212325072
P40121 822 Macrophage-capping protein OS=Homo sapiens GN=CAPG PE=1 SV=2 - [CAPG_HUMAN] 2.494215503 4.321403367
P08571 929 Monocyte differentiation antigen CD14 OS=Homo sapiens GN=CD14 PE=1 SV=2 - [CD14_HUMAN] 2.457310215 7.370190536
P16671 948 Platelet glycoprotein 4 OS=Homo sapiens GN=CD36 PE=1 SV=2 - [CD36_HUMAN] 2.437113479 6.231152034
P04839 1536 Cytochrome b-245 heavy chain OS=Homo sapiens GN=CYBB PE=1 SV=2 - [CY24B_HUMAN] 2.411794673 4.173676671
P80723 10409 Isoform 2 of Brain acid soluble protein 1 OS=Homo sapiens GN=BASP1 - [BASP1_HUMAN] 2.405743709 7.384046173
O75367 9555 Isoform 3 of Core histone macro-H2A.1 OS=Homo sapiens GN=H2AFY - [H2AY_HUMAN] 2.401394175 2.369266728
Q16555 1808 Dihydropyrimidinase-related protein 2 OS=Homo sapiens GN=DPYSL2 PE=1 SV=1 - [DPYL2_HUMAN] 2.396817943 3.415912987
P19878 4688 Neutrophil cytosol factor 2 OS=Homo sapiens GN=NCF2 PE=1 SV=2 - [NCF2_HUMAN] 2.374384459 7.997698158
P41218 4332 Myeloid cell nuclear differentiation antigen OS=Homo sapiens GN=MNDA PE=1 SV=1 - [MNDA_HUMAN] 2.343842135 5.874886151
P09382 3956 Galectin-1 OS=Homo sapiens GN=LGALS1 PE=1 SV=2 - [LEG1_HUMAN] 2.32453854 2.955172624
P09601 3162 Heme oxygenase 1 OS=Homo sapiens GN=HMOX1 PE=1 SV=1 - [HMOX1_HUMAN] 2.316324242 9.682357243
O75874 3417 Isocitrate dehydrogenase [NADP] cytoplasmic OS=Homo sapiens GN=IDH1 PE=1 SV=2 - [IDHC_HUMAN] 2.308540853 2.189173419
Q92820 8836 Gamma-glutamyl hydrolase OS=Homo sapiens GN=GGH PE=1 SV=2 - [GGH_HUMAN] 2.277618507 1.61515662
P05091 217 Aldehyde dehydrogenase, mitochondrial OS=Homo sapiens GN=ALDH2 PE=1 SV=2 - [ALDH2_HUMAN] 2.267819674 6.399892557
P23381 7453 Tryptophan--tRNA ligase, cytoplasmic OS=Homo sapiens GN=WARS PE=1 SV=2 - [SYWC_HUMAN] 2.200042769 5.822516788
P28676 25801 Grancalcin OS=Homo sapiens GN=GCA PE=1 SV=2 - [GRAN_HUMAN] 2.171101183 5.120882187
P09467 2203 Fructose-1,6-bisphosphatase 1 OS=Homo sapiens GN=FBP1 PE=1 SV=5 - [F16P1_HUMAN] 2.076504863 6.170451494
P07996 7057 Thrombospondin-1 OS=Homo sapiens GN=THBS1 PE=1 SV=2 - [TSP1_HUMAN] 2.067858348 13.02830043
Q0VD83 55911 Isoform 3 of Apolipoprotein B receptor OS=Homo sapiens GN=APOBR - [APOBR_HUMAN] 2.061568243 1.868535471
P04040 847 Catalase OS=Homo sapiens GN=CAT PE=1 SV=3 - [CATA_HUMAN] 2.058346879 2.126221241
A8MVU1 654817 Putative neutrophil cytosol factor 1C OS=Homo sapiens GN=NCF1C PE=5 SV=1 - [NCF1C_HUMAN] 2.037676042 3.736553538
P13473 3920 Lysosome-associated membrane glycoprotein 2 OS=Homo sapiens GN=LAMP2 PE=1 SV=2 - [LAMP2_HUMAN 2.027927785 4.021809165
P16070 960 Isoform 12 of CD44 antigen OS=Homo sapiens GN=CD44 - [CD44_HUMAN] 2.027501763 2.048521232
Q15942 7791 Zyxin OS=Homo sapiens GN=ZYX PE=1 SV=1 - [ZYX_HUMAN] 2.023041452 2.919039426
P00488 2162 Coagulation factor XIII A chain OS=Homo sapiens GN=F13A1 PE=1 SV=4 - [F13A_HUMAN] 2.011620491 4.828926446
P17931 3958 Galectin-3 OS=Homo sapiens GN=LGALS3 PE=1 SV=5 - [LEG3_HUMAN] 2.001404443 5.092891706
Q9ULZ3 29108 Isoform 3 of Apoptosis-associated speck-like protein containing a CARD OS=Homo sapiens GN=PYCARD - [AS 1.985489104 4.512577854
P50552 7408 Vasodilator-stimulated phosphoprotein OS=Homo sapiens GN=VASP PE=1 SV=3 - [VASP_HUMAN] 1.944804886 3.131708052
P29350 5777 Isoform 3 of Tyrosine-protein phosphatase non-receptor type 6 OS=Homo sapiens GN=PTPN6 - [PTN6_HUMAN 1.936628883 2.182771114
Q9ULV4 23603 Coronin-1C OS=Homo sapiens GN=CORO1C PE=1 SV=1 - [COR1C_HUMAN] 1.916972767 5.2241182
P07355 302 Annexin A2 OS=Homo sapiens GN=ANXA2 PE=1 SV=2 - [ANXA2_HUMAN] 1.907689604 2.289374654
P19971 1890 Thymidine phosphorylase OS=Homo sapiens GN=TYMP PE=1 SV=2 - [TYPH_HUMAN] 1.899774455 5.858781872
P38606 523 V-type proton ATPase catalytic subunit A OS=Homo sapiens GN=ATP6V1A PE=1 SV=2 - [VATA_HUMAN] 1.852371108 2.591206106
P08758 308 Annexin A5 OS=Homo sapiens GN=ANXA5 PE=1 SV=2 - [ANXA5_HUMAN] 1.852002829 3.797703389
P07858 1508 Cathepsin B OS=Homo sapiens GN=CTSB PE=1 SV=3 - [CATB_HUMAN] 1.811081517 4.738184226
P62942 2280 Peptidyl-prolyl cis-trans isomerase FKBP1A OS=Homo sapiens GN=FKBP1A PE=1 SV=2 - [FKB1A_HUMAN] 1.782836108 3.227615597
P06703 6277 Protein S100-A6 OS=Homo sapiens GN=S100A6 PE=1 SV=1 - [S10A6_HUMAN] 1.76927793 1.862373176
P29401 7086 Transketolase OS=Homo sapiens GN=TKT PE=1 SV=3 - [TKT_HUMAN] 1.741792972 3.639468143
P13284 10437 Gamma-interferon-inducible lysosomal thiol reductase OS=Homo sapiens GN=IFI30 PE=1 SV=3 - [GILT_HUMA 1.726063963 7.283362887
P09211 2950 Glutathione S-transferase P OS=Homo sapiens GN=GSTP1 PE=1 SV=2 - [GSTP1_HUMAN] 1.720518208 3.077989843
P10619 5476 Lysosomal protective protein OS=Homo sapiens GN=CTSA PE=1 SV=2 - [PPGB_HUMAN] 1.711447303 2.901181431
Q6XQN6 93100 Isoform 3 of Nicotinate phosphoribosyltransferase OS=Homo sapiens GN=NAPRT1 - [PNCB_HUMAN] 1.682487653 2.17241285
P52790 3101 Hexokinase-3 OS=Homo sapiens GN=HK3 PE=1 SV=2 - [HXK3_HUMAN] 1.675665794 7.353859678
P06733 2023 Alpha-enolase OS=Homo sapiens GN=ENO1 PE=1 SV=2 - [ENOA_HUMAN] 1.60248863 1.847594767  
